Overview

• Pfizer will extend most-favored-nation pricing to Medicaid and price new U.S. launches at parity with other wealthy countries, according to the company and the White House.
• Through the government’s new TrumpRx site, Pfizer plans to sell a large share of its primary care drugs and select specialty brands at cash prices averaging 50% off with savings up to 85%.
• Pfizer pledged $70 billion for U.S. research and manufacturing, a step expected to qualify it for a three-year reprieve from certain tariffs, according to Politico.
• Officials say TrumpRx will enable direct-to-consumer purchasing, but they have not specified which medicines will be listed or how the platform will interface with insurance coverage.
• Talks with other manufacturers continue as a 100% tariff on branded imports is slated to take effect Oct. 1 for companies not building U.S. facilities, and PhRMA is promoting its own direct-purchase portal.